ArticleAnnals of hematology2018
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Yoshihiro Hatta et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
32 papers cite it
this paperpooled ittrialcites it